Summary
Details about the arrangements in place for veterinary medicines supplied to NI, including the new Government schemes.
This guidance provides further detail regarding arrangements in place for veterinary medicines supplied to Northern Ireland, including on the two Government schemes.
This should be read in conjunction with other VMD guidance.
Background
The Government has provided further information in its policy paper published on 17 June 2025.
Government’s estimate of the supply of veterinary medicines into Northern Ireland
We have formed our supply picture through pharmaceutical industry engagement over a number of years. This has helped us to understand their intentions for continued supply to Northern Ireland from the end of 2025. We have also engaged with prescribers, trade bodies and others in the supply chain. Our current assessment is that around 10-15% of products authorised for Northern Ireland will be discontinued, however we do not expect significant implications for animal health and welfare as the majority of these products were either not marketed in Northern Ireland or there are multiple, alternative products on the market. The prescribing cascade and the two new schemes help build resilience where there is some uncertainty around exact product availability.
Some pharmaceutical companies have already set out their intentions to their customers, and we continue to encourage pharmaceutical companies that hold valid product authorisations in Northern Ireland to do so as well.
Information regarding the schemes
Guidance is available on the Veterinary Medicines Internal Market Scheme (VMIMS); and on the Veterinary Medicine Health Situation Scheme (VMHSS).
The schemes came into effect on 1 January 2026.
The VMHSS product list will be updated when new products are added. You can sign up to receive notifications via the ‘get emails about this page’ button.
You can obtain a GB product straight away from a wholesaler when using the VMIMS. This scheme does not apply to GB vaccines. Wholesalers can procure GB products and hold them in stock where they may be needed under the VMIMS.
The decision on whether to add a product to the VMHSS rests with the VMD and is used to address a significant health and welfare situation, but we are always keen to understand from vets, farmers and other stakeholders whether there might be a need. For example, the VMHSS might be more appropriate where there is a regular and/or high-volume need for a particular critical medicine, and the Special Import Scheme is unsuitable to meet the resultant health / welfare risks. Please use the report a supply problem form to provide us with any information.
These schemes will be monitored in the same way that suppliers of authorised products are monitored at present. The Department for Agriculture, Environment and Rural Affairs (DAERA) are responsible for inspecting veterinary premises in Northern Ireland that are not members of the Royal College of Veterinary Surgeons Practice Standards Scheme (PSS).
Many companies are continuing to supply veterinary medicines to Northern Ireland, and the number of product projected discontinuations are low. Where discontinuations are expected, these products are often not currently sold in Northern Ireland or only sold in very low quantities and/or multiple alternatives remain available. Therefore, it is not anticipated that there will be a significant reliance on these schemes.
Contents
-
Prescribing processes for vets in Northern Ireland.
-
Use and movement of veterinary medicines on the market in Northern Ireland before 1 January 2026.
-
Sourcing medicines via online pharmacies, impact on prices and trading with the EU, such as food products from 1 January 2026.
-
Details on the use of the Veterinary Medicine Internal Market Scheme (VMHSS) as it allows for the temporary authorisation to use suitable alternative products where the animal or public health situation requires for all types of veterinary medicines.